{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:06:51Z","timestamp":1779214011199,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020473","name":"Badan Riset dan Inovasi Nasional","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020473","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Breast cancer (BRCA) remains one of the most frequently diagnosed malignancies and a leading cause of cancer-related mortality among women worldwide. Its molecular heterogeneity and limited therapeutic options for aggressive subtypes highlight the need for novel treatment strategies. Drug repositioning offers a promising approach by identifying new therapeutic uses for existing drugs with established safety profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We applied an integrative transcriptomic and bioinformatics framework to identify candidate drug targets and repurposed drugs for BRCA. Differentially expressed genes (DEGs) were identified from four Gene Expression Omnibus (GEO) microarray datasets using the\n                      <jats:italic>limma<\/jats:italic>\n                      package with thresholds of |log2 fold change| &gt; 1 and false discovery rate (FDR)\u2009&lt;\u20090.05. Overlapping DEGs were expanded through protein\u2013protein interaction analysis using the STRING database. Functional annotation across ten biological evidence categories was performed using WebGestalt to prioritize BRCA risk genes through a multi-criteria scoring approach. Drug\u2013gene interactions were then analyzed using the Drug\u2013Gene Interaction Database (DGIdb), and tissue-specific gene expression was evaluated using the GTEx database.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-eight consistently dysregulated genes were identified and expanded into a 77-gene interaction network. Functional prioritization yielded 18 BRCA risk genes, including five druggable targets associated with 11 candidate drugs. ITGB7 emerged as a promising biomarker and therapeutic target, with vedolizumab identified as the top candidate drug.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study highlights the potential of integrative transcriptomic analysis to identify biomarkers and drug repositioning candidates in BRCA, providing a foundation for further experimental validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s43046-026-00368-5","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:16:09Z","timestamp":1779210969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unlocking new therapeutic horizons through integrative bioinformatics and transcriptomics for drug repositioning in breast cancer therapy"],"prefix":"10.1186","volume":"38","author":[{"given":"Wirawan","family":"Adikusuma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lalu Muhammad","family":"Irham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahmat Dani","family":"Satria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ika","family":"Nurlaila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dyah Laksmi","family":"Dewi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firdayani","family":"Firdayani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inna","family":"Syafarina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"368_CR1","doi-asserted-by":"publisher","first-page":"117822342199585","DOI":"10.1177\/1178223421995854","volume":"15","author":"J Schick","year":"2021","unstructured":"Schick J, Ritchie RP, Restini C. Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. Breast Cancer (Auckl). 2021;15:1178223421995854.","journal-title":"Breast Cancer (Auckl)"},{"issue":"1","key":"368_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"368_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000329471","volume":"6","author":"E Stickeler","year":"2011","unstructured":"Stickeler E. Prognostic and Predictive Markers for Treatment Decisions in Early Breast Cancer. Breast Care (Basel). 2011;6(3):193\u20138.","journal-title":"Breast Care (Basel)"},{"issue":"2","key":"368_CR4","first-page":"85","volume":"35","author":"RC Richie","year":"2003","unstructured":"Richie RC, Swanson JO. Breast cancer: a review of the literature. J Insur Med. 2003;35(2):85\u2013101.","journal-title":"J Insur Med"},{"issue":"3","key":"368_CR5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.clbc.2017.08.012","volume":"18","author":"B Rogoz","year":"2018","unstructured":"Rogoz B, Houze de l\u2019Aulnoit A, Duhamel A, Houze de l\u2019Aulnoit D. Thirty-Year Trends of Survival and Time-Varying Effects of Prognostic Factors in Patients With Metastatic Breast Cancer-A Single Institution Experience. Clin Breast Cancer. 2018;18(3):246\u201353.","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"368_CR6","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"368_CR7","doi-asserted-by":"crossref","unstructured":"Blaszczak E, Miziak P, Odrzywolski A, Baran M, Gumbarewicz E, Stepulak A. Triple-Negative Breast Cancer Progression and Drug Resistance in the Context of Epithelial-Mesenchymal Transition. Cancers (Basel). 2025;17(2):17020228.","DOI":"10.3390\/cancers17020228"},{"issue":"10","key":"368_CR8","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.7150\/ijbs.24612","volume":"14","author":"H Xue","year":"2018","unstructured":"Xue H, Li J, Xie H, Wang Y. Review of Drug Repositioning Approaches and Resources. Int J Biol Sci. 2018;14(10):1232\u201344.","journal-title":"Int J Biol Sci"},{"issue":"10","key":"368_CR9","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.2196\/jmir.9646","volume":"20","author":"M Zhao","year":"2018","unstructured":"Zhao M, Yang CC. Drug Repositioning to Accelerate Drug Development Using Social Media Data: Computational Study on Parkinson Disease. J Med Internet Res. 2018;20(10):e271.","journal-title":"J Med Internet Res"},{"key":"368_CR10","doi-asserted-by":"crossref","unstructured":"Adikusuma W, Chou WH, Lin MR, Ting J, Irham LM, Perwitasari DA, et al. Identification of Druggable Genes for Asthma by Integrated Genomic Network Analysis. Biomedicines. 2022;10(1):10010113.","DOI":"10.3390\/biomedicines10010113"},{"key":"368_CR11","doi-asserted-by":"publisher","first-page":"724277","DOI":"10.3389\/fimmu.2021.724277","volume":"12","author":"W Adikusuma","year":"2021","unstructured":"Adikusuma W, Irham LM, Chou WH, Wong HS, Mugiyanto E, Ting J, et al. Drug Repurposing for Atopic Dermatitis by Integration of Gene Networking and Genomic Information. Front Immunol. 2021;12:724277.","journal-title":"Front Immunol"},{"issue":"1","key":"368_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41\u201358.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"368_CR13","doi-asserted-by":"publisher","first-page":"10032","DOI":"10.1038\/s41598-023-37120-1","volume":"13","author":"W Adikusuma","year":"2023","unstructured":"Adikusuma W, Zakaria ZA, Irham LM, Nopitasari BL, Pradiningsih A, Firdayani F, et al. Transcriptomics-driven drug repositioning for the treatment of diabetic foot ulcer. Sci Rep. 2023;13(1):10032.","journal-title":"Sci Rep"},{"key":"368_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/1471-2164-7-96","volume":"7","author":"Z Hu","year":"2006","unstructured":"Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96.","journal-title":"BMC Genomics"},{"issue":"3","key":"368_CR15","first-page":"1355","volume":"34","author":"A Merdad","year":"2014","unstructured":"Merdad A, Karim S, Schulten HJ, Dallol A, Buhmeida A, Al-Thubaity F, et al. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer: MMP-9 as a potential biomarker for cancer invasion and metastasis. Anticancer Res. 2014;34(3):1355\u201366.","journal-title":"Anticancer Res"},{"issue":"1","key":"368_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3892\/or.2016.4806","volume":"36","author":"S Karim","year":"2016","unstructured":"Karim S, Merdad A, Schulten HJ, Jayapal M, Dallol A, Buhmeida A, et al. Low expression of leptin and its association with breast cancer: A transcriptomic study. Oncol Rep. 2016;36(1):43\u20138.","journal-title":"Oncol Rep"},{"issue":"10","key":"368_CR17","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1093\/carcin\/bgt208","volume":"34","author":"C Clarke","year":"2013","unstructured":"Clarke C, Madden SF, Doolan P, Aherne ST, Joyce H, O\u2019Driscoll L, et al. Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis. 2013;34(10):2300\u20138.","journal-title":"Carcinogenesis"},{"issue":"12","key":"368_CR18","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/emmm.201100801","volume":"3","author":"S Dedeurwaerder","year":"2011","unstructured":"Dedeurwaerder S, Desmedt C, Calonne E, Singhal SK, Haibe-Kains B, Defrance M, et al. DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Mol Med. 2011;3(12):726\u201341.","journal-title":"EMBO Mol Med"},{"issue":"7","key":"368_CR19","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"368_CR20","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607\u201313.","journal-title":"Nucleic Acids Res"},{"issue":"17\u201318","key":"368_CR21","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.drudis.2007.07.011","volume":"12","author":"H Ruffner","year":"2007","unstructured":"Ruffner H, Bauer A, Bouwmeester T. Human protein-protein interaction networks and the value for drug discovery. Drug Discov Today. 2007;12(17\u201318):709\u201316.","journal-title":"Drug Discov Today"},{"issue":"W1","key":"368_CR22","doi-asserted-by":"publisher","first-page":"W415","DOI":"10.1093\/nar\/gkae456","volume":"52","author":"JM Elizarraras","year":"2024","unstructured":"Elizarraras JM, Liao Y, Shi Z, Zhu Q, Pico AR, Zhang B. WebGestalt 2024: faster gene set analysis and new support for metabolomics and multi-omics. Nucleic Acids Res. 2024;52(W1):W415\u201321.","journal-title":"Nucleic Acids Res"},{"issue":"8046","key":"368_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41586-024-08244-9","volume":"637","author":"THH Coorens","year":"2025","unstructured":"Coorens THH, Guillaumet-Adkins A, Kovner R, Linn RL, Roberts VHJ, Sule A, et al. The human and non-human primate developmental GTEx projects. Nature. 2025;637(8046):557\u201364.","journal-title":"Nature"},{"issue":"D1","key":"368_CR24","doi-asserted-by":"publisher","first-page":"D1144","DOI":"10.1093\/nar\/gkaa1084","volume":"49","author":"SL Freshour","year":"2021","unstructured":"Freshour SL, Kiwala S, Cotto KC, Coffman AC, McMichael JF, Song JJ, et al. Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids Res. 2021;49(D1):D1144\u201351.","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"368_CR25","doi-asserted-by":"publisher","first-page":"101831","DOI":"10.1016\/j.jsps.2023.101831","volume":"31","author":"W Adikusuma","year":"2023","unstructured":"Adikusuma W, Firdayani F, Irham LM, Darmawi D, Hamidy MY, Nopitasari BL, et al. Integrated genomic network analysis revealed potential of a druggable target for hemorrhoid treatment. Saudi Pharm J. 2023;31(12):101831.","journal-title":"Saudi Pharm J"},{"key":"368_CR26","first-page":"101337","volume":"32","author":"AR Afief","year":"2022","unstructured":"Afief AR, Irham LM, Adikusuma W, Perwitasari DA, Brahmadhi A, Chong R. Integration of genomic variants and bioinformatic-based approach to drive drug repurposing for multiple sclerosis. Biochem Biophys Rep. 2022;32:101337.","journal-title":"Biochem Biophys Rep"},{"key":"368_CR27","first-page":"101334","volume":"32","author":"LM Irham","year":"2022","unstructured":"Irham LM, Adikusuma W, Perwitasari DA. Genomic variants-driven drug repurposing for tuberculosis by utilizing the established bioinformatic-based approach. Biochem Biophys Rep. 2022;32:101334.","journal-title":"Biochem Biophys Rep"},{"key":"368_CR28","first-page":"101307","volume":"31","author":"LM Irham","year":"2022","unstructured":"Irham LM, Adikusuma W, Perwitasari DA, Dania H, Maliza R, Faridah IN, et al. The use of genomic variants to drive drug repurposing for chronic hepatitis B. Biochem Biophys Rep. 2022;31:101307.","journal-title":"Biochem Biophys Rep"},{"issue":"2","key":"368_CR29","doi-asserted-by":"publisher","first-page":"100502","DOI":"10.1016\/j.jgeb.2025.100502","volume":"23","author":"RD Satria","year":"2025","unstructured":"Satria RD, Adikusuma W, Sukorini U, Avitasari DE, Kusuma Harahap IS, Setia Lesmana MH, et al. Genome-wide association study -Driven drug repositioning for the treatment of insomnia. J Genet Eng Biotechnol. 2025;23(2):100502.","journal-title":"J Genet Eng Biotechnol"},{"issue":"7488","key":"368_CR30","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nature12873","volume":"506","author":"Y Okada","year":"2014","unstructured":"Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506(7488):376\u201381.","journal-title":"Nature"},{"issue":"24","key":"368_CR31","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.21037\/atm-22-5716","volume":"10","author":"L Yang","year":"2022","unstructured":"Yang L, Wang M, Hu X, Yuan L, Chen S, Peng S, et al. EccDNA-oriented ITGB7 expression in breast cancer. Ann Transl Med. 2022;10(24):1344.","journal-title":"Ann Transl Med"},{"issue":"1","key":"368_CR32","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1080\/07853890.2021.1937694","volume":"53","author":"T Xu","year":"2021","unstructured":"Xu T, Liu J, Xia Y, Wang Z, Li X, Gao Q. Integrated analysis reveals the participation of IL4I1, ITGB7, and FUT7 in reshaping the TNBC immune microenvironment by targeting glycolysis. Ann Med. 2021;53(1):916\u201328.","journal-title":"Ann Med"},{"issue":"5","key":"368_CR33","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1177\/2040622315586970","volume":"6","author":"LN Cherry","year":"2015","unstructured":"Cherry LN, Yunker NS, Lambert ER, Vaughan D, Lowe DK. Vedolizumab: an alpha4beta7 integrin antagonist for ulcerative colitis and Crohn\u2019s disease. Ther Adv Chronic Dis. 2015;6(5):224\u201333.","journal-title":"Ther Adv Chronic Dis"},{"issue":"8","key":"368_CR34","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699\u2013710.","journal-title":"N Engl J Med"},{"issue":"3","key":"368_CR35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jcmgh.2019.10.012","volume":"9","author":"H Sun","year":"2020","unstructured":"Sun H, Kuk W, Rivera-Nieves J, Lopez-Ramirez MA, Eckmann L, Ginsberg MH. beta7 Integrin Inhibition Can Increase Intestinal Inflammation by Impairing Homing of CD25(hi)FoxP3(+) Regulatory T Cells. Cell Mol Gastroenterol Hepatol. 2020;9(3):369\u201385.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"368_CR36","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1146\/annurev-immunol-042617-053214","volume":"37","author":"D Masopust","year":"2019","unstructured":"Masopust D, Soerens AG, Tissue-Resident T. Cells and Other Resident Leukocytes. Annu Rev Immunol. 2019;37:521\u201346.","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"368_CR37","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1158\/2326-6066.CIR-20-0879","volume":"9","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Xie R, Zhang H, Zheng Y, Lin C, Yang L, et al. Integrin beta7 Inhibits Colorectal Cancer Pathogenesis via Maintaining Antitumor Immunity. Cancer Immunol Res. 2021;9(8):967\u201380.","journal-title":"Cancer Immunol Res"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00368-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-026-00368-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00368-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:16:11Z","timestamp":1779210971000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43046-026-00368-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["368"],"URL":"https:\/\/doi.org\/10.1186\/s43046-026-00368-5","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"18 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}